長江生命科技(00775.HK):針對TROP2(滋養層細胞表面抗原2)的新型癌症疫苗取得良好的早期成果
格隆匯4月11日丨長江生命科技(00775.HK)發佈公吿,其針對滋養層細胞表面抗原2(“TROP2”)的新型癌症疫苗在臨牀前階段實驗室測試中取得良好的早期成果。TROP2乃一種在多類癌症中有過度表現的細胞表面糖蛋白,常見於乳癌、肺癌、胰臟癌及結直腸癌。此蛋白在細胞繁衍、轉移及入侵方面扮演關鍵角色,過度表現的狀態常引致惡性腫瘤行為及差劣的臨牀效果。由於此蛋白在癌細胞的高度表現及在正常組織中極少存在,TROP2遂成為腫瘤學中具發展潛力的治療性標靶。
公司認為TROP2是一種令人振奮的治療性標靶癌症疫苗,在小鼠研究中觀察所見,公司的TROP2癌症疫苗展現前所未見的成功抗癌效能。公司期望TROP2癌症疫苗能迅速進展至臨牀研究階段,以儘早帶來腫瘤治療新方向,並造福病患。於本公吿刊發日期前,公司已向香港知識產權署提交circRNA及融合蛋白TROP2癌症疫苗的原授標準專利申請,並向美國專利商標局提交相關臨時專利申請。經過詳細評估,公司認為該TROP2癌症疫苗的成功商品化可為公司帶來潛在的重大經濟效益。
有關TROP2癌症疫苗的數據預期於即將舉行的各癌症會議中發表。公司研發中的早期癌症疫苗種類不斷增加,近年於各大型腫瘤學研討會中已展示相關臨牀前研究數據,並提交多項專利申請。此等創新癌症疫苗均於香港的研究實驗室進行研發,並以多種類的腫瘤抗原、免疫檢查點蛋白,以及其他存在於腫瘤免疫微環境下的主要成份為標靶。公司已向聯交所申請公司股份自2025年4月11日上午九時正起恢復買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.